Clinical Trial Update: Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients [Phase 2]

View source ↗

Summary

This update describes a Phase 2 clinical trial evaluating dapagliflozin for primary prevention of cardiotoxicity from anthracycline chemotherapy in breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Heart Failure

Drugs mentioned

• FARXIGA (dapagliflozin)

Snippet

Sponsor: University Medical Centre Ljubljana | Conditions: Heart Failure, Anthracycline-induced Cardiac Toxicity | Phase 2 | Status: RECRUITING